| Dr Allen David Davies, DO | |
|
6011 S Redwood Rd, Taylorsville, UT 84123-5220 | |
| (801) 293-7001 | |
| Not Available |
| Full Name | Dr Allen David Davies |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 6011 S Redwood Rd, Taylorsville, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720175037 | NPI | - | NPPES |
| 49999931200001 | Other | UT | REGENCE BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 4999993-1204 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Allen David Davies, DO 2869 Estates Dr, Park City, UT 84060-6880 Ph: (435) 649-0201 | Dr Allen David Davies, DO 6011 S Redwood Rd, Taylorsville, UT 84123-5220 Ph: (801) 293-7001 |
News Archive
Oxford researchers are developing a tool to make it much easier and cheaper to diagnose pneumonia - the number one killer of children under 5. Their latest research is published in Journal of the Royal Society Interface.
Adocia, a biotechnology company specializing in the development of ‘best-in-class' medicines from already approved therapeutic proteins, announced today that it had agreed with Eli Lilly and Company not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone(R) technology for the formulation of fast acting insulin analog formulated with the BioChaperone(R) technology. Consequently, the two companies have terminated the collaboration.
The Norwegian Directorate of Health has awarded Accenture a five-year contract to build and implement Norway's electronic health record (EHR) system.
Carrying around a spare tire is a good thing - you never know when you'll get a flat. Turns out we're all carrying around "spare tires" in our genomes, too. Today, in ACS Central Science, researchers report that an extra set of guanines (or "G"s) in our DNA may function just like a "spare" to help prevent many cancers from developing.
Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.
› Verified 1 days ago
Deepa Gupta, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3845 W 4700 S, Taylorsville, UT 84118 Phone: 801-840-2020 |